# Acumen Pharmaceuticals Inc. (ABOS)

Source: https://www.quantisnow.com/company/ABOS
Generated: 2026-11-12T09:50:32.157Z

- Ticker: ABOS
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2021
- SEC CIK: 0001576885
- Website: acumenpharm.com

## About

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.

## Latest ABOS news and filings

- 2026-11-05 21:01 UTC [SEC Form 8-K] [Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/acumen-pharmaceuticals-inc-filed-sec-form-8-k-termination-of-a-6775934)
- 2026-11-02 12:31 UTC [Analyst Downgrade] [Acumen Pharmaceuticals downgraded by BofA Securities with a new price target](https://www.quantisnow.com/insight/acumen-pharmaceuticals-downgraded-by-bofa-securities-with-a-new-price-6766122)
- 2026-10-30 13:33 UTC [Analyst Downgrade] [Acumen Pharmaceuticals downgraded by Stifel with a new price target](https://www.quantisnow.com/insight/acumen-pharmaceuticals-downgraded-by-stifel-with-a-new-price-target-6764793)
- 2026-10-30 11:06 UTC [SEC Form 8-K] [Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/acumen-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6764488)
- 2026-10-30 11:00 UTC [Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint](https://www.quantisnow.com/insight/acumen-pharmaceuticals-announces-topline-results-from-phase-2-altitude-ad-clinical-6764440)
- 2026-10-29 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Acumen Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-acumen-pharmaceuticals-inc-6762106)
- 2026-10-26 20:21 UTC [SEC Form S-3] [SEC Form S-3 filed by Acumen Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-acumen-pharmaceuticals-inc-6757734)
- 2026-10-26 20:03 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Acumen Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-acumen-pharmaceuticals-inc-6757553)
- 2026-10-26 11:09 UTC [SEC Form 8-K] [SEC Form 8-K filed by Acumen Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-acumen-pharmaceuticals-inc-6756919)
- 2026-10-26 11:00 UTC [Earnings Date] [Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights](https://www.quantisnow.com/insight/acumen-pharmaceuticals-reports-third-quarter-2026-financial-results-and-business-6756868)
- 2026-10-19 20:00 UTC [Earnings Date] [Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026](https://www.quantisnow.com/insight/acumen-pharmaceuticals-to-report-third-quarter-financial-results-on-october-6750464)
- 2026-09-16 13:26 UTC [SEC Form 8-K] [Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/acumen-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6717164)
- 2026-09-10 20:00 UTC [Earnings Date] [Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026](https://www.quantisnow.com/insight/acumen-pharmaceuticals-to-hold-virtual-investor-day-on-september-16-6711463)
- 2026-09-02 20:00 UTC [Conference Announcement] [Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/acumen-pharmaceuticals-to-participate-in-upcoming-investor-conferences-6702954)
- 2026-08-12 20:24 UTC [SEC Form S-8] [SEC Form S-8 filed by Acumen Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-acumen-pharmaceuticals-inc-6678129)
- 2026-08-12 20:13 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Acumen Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-acumen-pharmaceuticals-inc-6677959)
- 2026-08-12 11:02 UTC [SEC Form 8-K] [Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/acumen-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6676954)
- 2026-08-12 11:00 UTC [Earnings Date] [Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights](https://www.quantisnow.com/insight/acumen-pharmaceuticals-reports-second-quarter-2026-financial-results-and-business-6676926)
- 2026-08-05 20:00 UTC [Earnings Date] [Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026](https://www.quantisnow.com/insight/acumen-pharmaceuticals-to-report-second-quarter-financial-results-on-august-6664741)
- 2026-06-17 21:10 UTC [SEC Form 4] [Director Porter Derrell exercised 19,500 shares at a strike of $1.07 and sold $75,240 worth of shares (32,300 units at $2.33), decreasing direct ownership by 27% to 35,500 units (SEC Form 4)](https://www.quantisnow.com/insight/director-porter-derrell-exercised-19500-shares-at-a-strike-of-6607209)
- 2026-06-17 20:02 UTC [SEC Form 144] [SEC Form 144 filed by Acumen Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-acumen-pharmaceuticals-inc-6606488)
- 2026-06-16 11:34 UTC [SEC Form 8-K] [Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/acumen-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6603885)
- 2026-06-10 20:51 UTC [SEC Form 4] [Director Fountain Nathan B sold $14,273 worth of shares (6,400 units at $2.23), decreasing direct ownership by 12% to 48,150 units (SEC Form 4)](https://www.quantisnow.com/insight/director-fountain-nathan-b-sold-14273-worth-of-shares-6400-6597495)
- 2026-06-05 21:12 UTC [SEC Form 4] [Director Ra Capital Management, L.P. was granted 35,500 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-ra-capital-management-lp-was-granted-35500-shares-sec-6591904)
- 2026-06-05 20:32 UTC [SEC Form 4] [Director Fountain Nathan B was granted 35,500 shares, increasing direct ownership by 186% to 54,550 units (SEC Form 4)](https://www.quantisnow.com/insight/director-fountain-nathan-b-was-granted-35500-shares-increasing-direct-6591576)
- 2026-06-05 20:31 UTC [SEC Form 4] [Director Drapkin Kimberlee C was granted 35,500 shares, increasing direct ownership by 277% to 48,300 units (SEC Form 4)](https://www.quantisnow.com/insight/director-drapkin-kimberlee-c-was-granted-35500-shares-increasing-direct-6591568)
- 2026-06-05 20:30 UTC [SEC Form 4] [Director Stalfort John A Iii was granted 35,500 shares, increasing direct ownership by 19% to 220,624 units (SEC Form 4)](https://www.quantisnow.com/insight/director-stalfort-john-a-iii-was-granted-35500-shares-increasing-6591554)
- 2026-06-05 20:30 UTC [SEC Form 4] [Director Porter Derrell was granted 35,500 shares, increasing direct ownership by 277% to 48,300 units (SEC Form 4)](https://www.quantisnow.com/insight/director-porter-derrell-was-granted-35500-shares-increasing-direct-ownership-6591514)
- 2026-06-05 20:29 UTC [SEC Form 4] [Director Ives Jeffrey L. was granted 35,500 shares, increasing direct ownership by 277% to 48,300 units (SEC Form 4)](https://www.quantisnow.com/insight/director-ives-jeffrey-l-was-granted-35500-shares-increasing-direct-6591498)
- 2026-06-05 20:28 UTC [SEC Form 4] [Director Golumbeski George was granted 35,500 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-golumbeski-george-was-granted-35500-shares-sec-form-4-6591480)
- 2026-06-05 20:27 UTC [SEC Form 4] [Director Stoppel Laura was granted 35,500 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-stoppel-laura-was-granted-35500-shares-sec-form-4-6591470)
- 2026-06-03 20:43 UTC [SEC Form 8-K] [Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/acumen-pharmaceuticals-inc-filed-sec-form-8-k-submission-of-matters-6587393)
- 2026-05-12 21:16 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Acumen Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-acumen-pharmaceuticals-inc-6548903)
- 2026-05-12 11:07 UTC [SEC Form 8-K] [Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/acumen-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6546614)
- 2026-05-12 11:00 UTC [Earnings Date] [Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights](https://www.quantisnow.com/insight/acumen-pharmaceuticals-reports-first-quarter-2026-financial-results-and-business-6546527)
- 2026-05-07 20:00 UTC [Conference Announcement] [Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference](https://www.quantisnow.com/insight/acumen-pharmaceuticals-to-participate-in-the-bank-of-america-securities-6538527)
- 2026-05-05 20:00 UTC [Earnings Date] [Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026](https://www.quantisnow.com/insight/acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-6531696)
- 2026-04-23 20:31 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Acumen Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-acumen-pharmaceuticals-inc-6512863)
- 2026-04-23 20:30 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Acumen Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-acumen-pharmaceuticals-inc-6512853)
- 2026-04-07 20:05 UTC [SEC Form SCHEDULE 13G filed by Acumen Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-acumen-pharmaceuticals-inc-6491215)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ABOS
- Earnings history: https://www.quantisnow.com/earnings/ABOS
- Dividend history: https://www.quantisnow.com/dividends/ABOS
- Insider transactions: https://www.quantisnow.com/insiders/ABOS
- Options chain: https://www.quantisnow.com/options/ABOS
- SEC 8-K filings only: https://www.quantisnow.com/company/ABOS/8-k
- RSS and alerts for ABOS: https://www.quantisnow.com/docs/rss-feeds.md